



NUCLEA  
BIOTECHNOLOGIES

413.749.4705  
fax: 413.445.9930  
[www.nucleabio.com](http://www.nucleabio.com)  
Nuclea Biotechnologies, LLC  
105 South Street • Pittsfield, MA 01201

## PRESS RELEASE

For Immediate Release  
November 10, 2010

Contact: Greg D'Agostino  
617.695.0369 office  
617.388.6477 cell

Conor Yunits  
508.728.2964 cell

---

### **NUCLEA BIOTECHNOLOGIES RECEIVES \$733,000 FEDERAL GRANT UNDER NEW HEALTH CARE LAW; WILL EXPAND PITTSFIELD WORKFORCE BY 25%**

*Grant will fund 4-5 new positions at Pittsfield's Nuclea Genomics Center*

Pittsfield - Nuclea Biotechnologies, LLC announced today that it has been awarded more than \$733,000 in federal government grants as part of the Qualifying Therapeutic Discovery Project (QTDP). The funds will support 4-5 new jobs being created in the City of Pittsfield at the Nuclea Genomics Center. Nuclea has also signed an agreement to lease an additional 2800 square feet of space to expand the Center.

“This award is an acknowledgement of both our success in aiding cancer, cardiovascular, and metabolic research and our long-term job growth potential,” said Patrick Muraca, president and CEO of Nuclea. “With this funding, we will continue to grow jobs in Pittsfield, and work towards our goal of tripling our staff in the city by the end of the year.”

QTDP was created by Congress as part of the Patient Protection and Affordable Care Act of 2010 and targets projects that show potential to result in new therapies to treat areas of unmet medical need or prevent, detect, or treat chronic or acute diseases and conditions; reduce the long-term growth of health care costs in the United States; or significantly advance the goal of curing cancer within 30 years. In awarding the grants, the Internal Revenue Service also considered which projects showed the greatest potential to create and sustain high-quality, high-paying U.S. jobs and advance U.S. competitiveness in life, biological and medical sciences.

“Massachusetts is receiving more per-capita than any other state from the QTDP program, dollars that will translate into job growth throughout the Commonwealth,” said Dr. Susan Windham-Bannister, president & CEO of the Massachusetts Life Sciences Center, the agency charged with implementing the state’s ten-year, \$1 billion Life Sciences Initiative. “The many awards for companies in Massachusetts speak to the ongoing strength of our Life Sciences Supercluster. We were pleased to join Nuclea recently for the opening of their new Genomics Center in Pittsfield, and to support the company through their participation in the Center’s Internship Challenge Program. We look forward to an ongoing partnership with this great company as they continue to prosper and grow in Massachusetts.”

Aside from supporting the new positions, Nuclea will use the funds to advance its cancer diagnostic and biomarker discovery programs. Nuclea’s focus is molecular oncology with primary discovery and development activities in the five major cancer types– Colon, Breast, Leukemia, Lung and Prostate.

Founded in 2005, Nuclea Biotechnologies has raised more than \$21 million in private financing to date, including an additional \$5.4 million that closed last week. Nuclea currently has 20 employees at two locations in Pittsfield, including the Nuclea Genomics Center which opened in August. The company has 20 additional employees in Worcester.

**Nuclea Biotechnologies, LLC** is headquartered in Pittsfield, Massachusetts with additional operations in Worcester, Massachusetts. Nuclea has three lines of business, each of which is operated by a separate wholly-owned subsidiary: Nuclea Diagnostic Laboratories (“NDL”) which has developed and is commercializing eleven unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer; Nuclea Biomarkers (“NBM”) which performs research leading to novel molecular oncology therapeutics and diagnostics for the pharmaceutical and biotechnology industries and performs services by analyzing and testing the efficacy and validating other indications of existing therapeutics utilizing a highly characterized and consented patient database; and Nuclea Biotherapeutics (“NBT”) which has developed several therapeutics now in animal trials.